The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Setback for Novartis Hepatitis Drug

April 20, 2012

On Thursday, the Food and Drug Administration placed the development of an experimental hepatitis C drug on hold after the death of a patient that could be linked to it.

Switzerland-based Novartis AG is developing the drug, known as DEB025 or alisporivir. Rather than targeting hepatitis C virus directly, as other treatments do, it focuses on proteins that are essential for viral replication. Novartis proceeded with late-stage testing after intermediate studies last year showed alisporivir was effective in eliminating HCV.

Novartis said a small number of patients who received DEB025, in addition to pegylated interferon and ribavirin, developed pancreatitis, which is thought to be a contributing factor in the patient's death. This was the only death in the DEB025 program, which has involved about 1,800 patients to date, Novartis said.

David Kaegi, an analyst with Zurich's Bank Sarasin, said the drug's role in the death "remains to be determined. The case is open."

Back to other news for April 2012

Adapted from:
Wall Street Journal
04.19.2012; Marta Falconi

  • Email Email
  • Comments Comments
  •  (1)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
Talk to a Physician About HIV/Hepatitis Coinfection in Our "Ask the Experts" Forums
More on Hepatitis C Drugs in Development


Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: